Next-Gen Delivery System Market Trends for 2026

The next-gen delivery market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2026 and 2035. Market forecasts suggest robust development fueled by increased investments, innovation, and rising demand across various industries.

The growing incidence of diseases is increasing the use of novel treatment approaches, which in turn, is increasing the demand for next-gen delivery systems. The growing collaborations between the companies are also increasing their development and launches. Moreover, the use of AI is contributing by enhancing its properties, increasing its acceptance rates. This, in turn, is also enhancing the use of various next-gen delivery systems in the biologics and gene therapies. Additionally, their demand in different regions is also increasing, due to growing use of biologics, advancing healthcare, or even due to their rising demand. Thus, all these developments are promoting the next-gen delivery system market growth.

Key Takeaways

• North America dominated the next-gen delivery system market with 34% share in 2025.
• Asia Pacific held 29% of the market share and is expected to be the fastest-growing region with 13.1% CAGR during the forecast period.
• By product type, the oral drug delivery systems segment held the major market share of 32% in 2025.
• By product type, the injectable drug delivery systems segment held the second largest market share of 26% and is expected to grow at the fastest CAGR of 12.6% during the forecast period.
• By technology, the controlled & sustained release segment held the major market share of 30% in 2025.
• By technology, the nanotechnology-based delivery segment held the second largest market share of 28% and is expected to grow at the fastest CAGR of 13.2% during the forecast period.
• By route of administration, the oral segment held the major next-gen delivery system market share of 38% in 2025.
• By route of administration, the parenteral segment held the second largest market share of 27% and is expected to grow at the fastest CAGR of 12.5% during the forecast period.
• By application, the oncology segment held the major market share of 29% in 2025, and is expected to grow at the fastest CAGR of 13.4% during the forecast period.
• By end-user, the hospitals segment held the major market share of 42% in 2025.
• By end-user, the home care settings segment held the second largest market share of 26% and is expected to grow at the fastest CAGR of 12.8% during the forecast period.

Market Overview

The next generation drug delivery systems provide controlled as well as sustained release of the drugs. At the same time, their use in target-specific action is also growing, which in turn, helps to minimize the side effects. Furthermore, the use of nanocarrier systems and liposomal drug delivery systems is also increasing as they are being used in the delivery of various drugs with poor solubility or instability. Thus, their use in the treatment of cancer, CNS diseases, as well as gene therapies, is increasing.

Market Dynamics

Driver

To improve the safety, efficacy, as well as bioavailability of drugs, various innovations are being developed. At the same time, research and development to formulate a nanocarrier system for site-specific action are also increasing. Similarly, to enhance the stability of various formulations, the use of liposomal or hydrogel delivery systems is also being considered. Furthermore, the use as well as demand for transdermal drug delivery systems with the help of patches is also increasing. Thus, all these innovations are driving the next-gen delivery system market.

Restraint

For the formulation and development of these next-generation delivery systems, the equipment as well as the infrastructure required are sophisticated. At the same time, the procedure or the methods for their development or complex, which requires expertise. Furthermore, the stability issues as well as unwanted interactions can also affect their development, restraining the market growth.

Opportunity

There is a rise in the incidence rate of various diseases, such as cancer, autoimmune disease, diabetes, and rare diseases etc. These diseases increase the demand for new treatment approaches, leading to the growth of next-gen delivery system options. Hence, with the help of these next-gen delivery systems, drugs with enhanced stability, bioavailability, efficacy, and targeted action can be delivered. Additionally, they can also show prolonged release patterns, reducing the dosing frequency and increasing patient compliance with the treatment. Thus, this promotes the next-gen delivery system market growth.

• In March 2025, a collaboration was announced by Harbour BioMed, which is a global biopharmaceutical company that is committed to discovering, developing, and commercializing novel antibody therapeutics in oncology and immunology, with AstraZeneca. The next-generation multi-specific antibodies will be discovered and developed for immunology, oncology, and beyond by this collaboration.

The graph represents the total number of autoimmune disorder cases observed in the U.S. It indicates that there will be a rise in cases of autoimmune disorders. Hence, it increases the demand for next-gen delivery systems to enhance the properties of the treatment options for the effective management of these rising disorders. Thus, this in turn will ultimately promote the market growth.

Next-Gen Delivery System Market Trends and Future Outlook

Increased Focus on Patient-Centric Therapies: In order to enhance patient experience by offering minimally invasive, easy-to-use, and painless solutions, the use of next-gen delivery systems is increasing, where they offer personalized dosing and improve patient compliance and convenience.

Growing Use of Biologics: The growing acceptance rates of the biologics are increasing their development to offer targeted and controlled drug release, which is increasing the demand for next-gen delivery systems, where the growing use of proteins and antibodies is also increasing their use to maintain their stability and effectiveness.

Technological Advancements: The growing technological advancements are driving the development of new next-gen delivery systems, such as smart pumps, implants, and microneedles, along with the integration of advanced technologies to offer real-time monitoring and personalized dosing.

What are the Recent Collaborations and Deals in the Next-Gen Delivery System Market?

• In May 2025, a memorandum of understanding (MoU) was signed between Sigachi MENA FZCO and Czech-based Respilon Group S.R.O., which was disclosed by an exchange filing with the Bombay Stock Exchange (BSE). This collaboration will focus on developing new nanofibre-based drug delivery technologies. 
• In April 2025, a modular protein adapter technology, which helps in attaching various substances to the surface of extracellular vesicles (exosomes) stably, was developed by a collaboration between the research team led by Professor Kyungmoo Yea from the Department of New Biology and Professor Daeha Seo from the Department of Chemistry and Physics at DGIST (President Kunwoo Lee) with Professor Moon-chang Baek’s team from the School of Medicine at Kyungpook National University.

Why is the Use of AI Increasing in the Next-Gen Delivery System Market?

The use of AI in the next-gen delivery systems is increasing. With the help of AI, smart drug delivery systems are being developed that help to transport drugs to the specific tissues and cells, minimizing the side effects. Moreover, with the use of genetic algorithms, the biological processes and drug activity can be predicted and optimized. Additionally, to merge the novel diagnostic tools with targeted therapies, AI in drug design is being integrated with biotechnology to develop personalized medicine, known as theragnostics.

Segmental Insights

Product Type Insights

The Oral Drug Delivery Systems Segment Led the Market in 2025

The oral drug delivery systems segment held the major next-gen delivery system market share of 32% in 2025 due to ease of administration and patient compliance. Pharmaceutical companies continue developing controlled-release tablets. Cost-effectiveness supports large-scale adoption globally.

The injectable drug delivery systems segment held the second largest market share of 26% and is expected to grow at the fastest CAGR of 12.6% during the forecast period. Rising biologics and biosimilars drive injectable demand. Self-administration devices improve patient adherence significantly. Increasing chronic disease burden boosts usage.

The pulmonary drug delivery systems segment captured 14% of the market share in 2025. Growth is driven by increasing respiratory disorders worldwide. Advancements in inhaler technology enhance drug efficiency. Rising pollution levels support demand.

The transdermal drug delivery systems segment captured 12% of the market share in 2025 because non-invasive delivery improves patient comfort and compliance. Innovations like microneedles expand therapeutic applications. Increasing chronic pain management needs fuel growth.

The implantable drug delivery systems segment captured 9% of the next-gen delivery system market share in 2025 because long-term drug release solutions reduce dosing frequency. Rising cardiovascular and orthopedic procedures increase adoption. Technological advances improve safety and precision.

The ocular drug delivery systems segment captured 7% of the market share in 2025 because the increasing prevalence of eye disorders drives demand. Advanced formulations improve drug retention in the eyes. An aging population supports sustained growth.

Technology Insights

The Controlled & Sustained Release Segment Led the Market in 2025

The controlled & sustained release segment held the major market share of 30% in 2025 because sustained release improves therapeutic outcomes. Reduces dosing frequency and enhances patient compliance. Widely used across chronic therapies.

The nanotechnology-based delivery segment held the second largest next-gen delivery system market share of 28% and is expected to grow at the fastest CAGR of 13.2% during the forecast period because manocarriers enhance drug solubility and targeting efficiency. Increased R&D investments accelerate innovation. Oncology applications strongly drive adoption. 

The targeted drug delivery segment captured 24% of the market share in 2025 because precision medicine trends increase targeted therapy usage. Antibody-drug conjugates gain traction in oncology. Improved efficacy reduces side effects.

The smart drug delivery systems segment captured 18% of the next-gen delivery system market share in 2025 because integration with digital health devices boosts demand. Real-time monitoring enhances treatment efficiency. Rising adoption of connected healthcare solutions drives growth.

Route of Administration Insights

The Oral Segment Dominated the Market in 2025

The oral segment held the major market share of 38% in 2025. Oral route remains preferred due to convenience and cost. High patient acceptance ensures strong demand. Suitable for wide therapeutic areas.

The parenteral segment held the second largest market share of 27% and is expected to grow at the fastest CAGR of 12.5% during the forecast period. Increasing biologics require injectable delivery. Rapid drug action supports critical care applications. Growth in self-injection devices drives expansion.

The inhalation segment captured 13% of the next-gen delivery system market share in 2025 because rising respiratory diseases increase inhalation demand. Technological advancements improve drug delivery efficiency. Urban pollution contributes to growth.

The transdermal segment captured 12% of the market share in 2025, as non-invasive delivery enhances patient compliance. Suitable for long-term therapies. Expanding use in pain management fuels demand.

The ocular segment captured 10% of the market share in 2025 because increasing eye disorders support demand. Advances in formulation improve effectiveness. An aging population boosts adoption.

Application Insights

The Oncology Segment Dominated the Market in 2025

The oncology segment held the major next-gen delivery system market share of 29% in 2025, and is expected to grow at the fastest CAGR of 13.4% during the forecast period. Rising cancer prevalence drives demand for advanced delivery systems. Targeted therapies improve treatment outcomes, and continuous innovation fuels market expansion.

The cardiovascular diseases segment held the second-largest market share of 18% in 2025, as high global incidence supports steady demand. Controlled-release drugs improve patient outcomes, and the increasing elderly population drives usage.

The diabetes segment captured 16% of the market share in 2025. A growing diabetic population increases demand for insulin delivery systems. Smart injectors improve adherence, and continuous glucose monitoring integration boosts growth.

The infectious diseases segment captured 14% of the market share in 2025 because the increasing need for vaccines and antivirals drives demand. Advanced delivery systems improve efficacy, and the global Health Initiatives support growth.

The neurological disorders segment captured 12% of the next-gen delivery system market share in 2025 because drug delivery to the brain drives innovation. Increasing neurological cases boost demand, and advanced technologies improve targeting efficiency.

The respiratory diseases segment captured 11% of the market share in 2025. The increasing asthma and COPD cases are supporting the growth of the segment. Furthermore, inhalation systems dominate treatment, and environmental factors drive demand.

End-User Insights

The Hospitals Segment Dominated the Market in 2025

The hospitals segment held the major next-gen delivery system market share of 42% in 2025. Hospitals handle large patient volumes and advanced treatments. Access to complex delivery systems supports dominance. Increasing hospitalization rates drive demand.

The home care settings segment held the second largest market share of 26% and is expected to grow at the fastest CAGR of 12.8% during the forecast period because there is a growing shift toward home-based care, which increases demand. Self-administration devices improve convenience, and cost savings drive adoption.

The speciality clinics segment captured 18% of the market share in 2025 because specialized treatments boost demand for advanced delivery systems. Growing outpatient procedures support growth. Apart from this, technological adoption enhances efficiency.

The ambulatory surgical centers segment captured 14% of the next-gen delivery system market share in 2025 due to the rising demand for minimally invasive procedures. Also, there is a faster patient turnover in ASCs due to cost-effective care models, ultimately leading to the growth of the segment.

Regional Insights

Increasing Use of Biologics Drives North America

North America dominated the next-gen delivery system market in 2025, with a revenue share of 34%. The growing use of biologics in the treatment of various diseases in North America is increasing the demand for next-gen delivery systems. This contributes to the market growth. The region is also growing due to the strong presence of key market players. These key players collaborate and contribute to the growing demand for therapeutics and other needs for healthcare needs.

The U.S. Next-Gen Delivery System Market Trends

The U.S. dominated the market in North America with 27% of the North American market share in 2025. The industries in the U.S. are focusing on the development of various next-gen delivery systems. At the same time, the use of advanced technologies is enhancing the developmental process as well as their safety and efficacy. The U.S. is the largest economy in the North American region with advanced healthcare systems and a highly developed pharma and biotechnology sector.

The Canada Next-Gen Delivery System Market Trends

Of the 34%, Canada held 7% of the market share in 2025. The industries as well as institutes are developing various next-gen delivery systems for drugs with stability issues. This, in turn, enhances the collaborations between them, which are further supported by the funding provided by the government. The government of Canada is collaborating with other countries to enhance healthcare services and products.

Advancing Healthcare Boosts the Asia Pacific

Asia Pacific held 29% of the market share in 2025 and is expected to host the fastest-growing next-gen delivery system market with 13.1% CAGR during the forecast period. The healthcare sector in the Asia Pacific is expanding due to the growing use of various treatment approaches, as well as research and development. This, in turn, is enhancing the market growth. Asia Pacific has the largest population, which demands a large number of products and services from the healthcare industry. Due to this, the countries in this region, like China, Japan, India, Thailand, etc, are taking efforts to develop high-end healthcare products.

The China Next-Gen Delivery System Market Trends

China held 11% of the Asia Pacific market in 2025 because China consists of a large population, which in turn increases the risk of diseases. This results in growing adoption of next-gen delivery systems for their effective treatment. Furthermore, they are also developing new minimally invasive next-gen delivery systems. China contributes the largest share because of its innovation and healthcare advancements. After the U.S., China holds second place in the pharmaceutical and biotechnology sectors.

The India Next-Gen Delivery System Market Trends

India held 5% of the Asia Pacific market share in 2025. The growing diseases in India are increasing the demand for next-gen delivery systems. Thus, this increases their research and development, which are further supported by the government to make them affordable and easily accessible. India has the largest population, with a growing demand for medicine in chronic conditions. As the population grows, the government of India has to take various measures to tackle the demand for products.

Europe Driven by Growing Research

Europe held the second largest market share of 25% in 2025 and is expected to grow significantly in the next-gen delivery system market during the forecast period. Europe is experiencing a rise in the research and development of next-gen delivery systems for the treatment of various chronic diseases. This promotes the market growth.

The Germany Next-Gen Delivery System Market Trends

Germany captured 7% of the Europe market in 2025. The healthcare sector in Germany is utilizing next-gen delivery systems for the treatment of cancer or autoimmune diseases. At the same time, new targeted drug delivery systems are also being adopted as well as developed by the industries for diabetes and Alzheimer's disease.

The UK Next-Gen Delivery System Market Trends

Out of the 25% Europe market share, the UK held 5% in 2025. The demand for the use of gene therapies or biologics is increasing in the UK. This, in turn, is increasing the development in the next-gen delivery systems for their targeted release, as well as with new injectable systems. These are furthermore supported by the regulatory bodies.

Expanding Healthcare Boosts Latin America

Latin America captured 7% of the market share in 2025 and is expected to grow significantly in the next-gen delivery system market during the forecast period, due to expanding healthcare infrastructure, which increases the demand for advanced drug delivery systems for the management of growing chronic diseases. The growing shift toward self-administration is also increasing their innovations, which is enhancing the market growth.

Brazil Next-Gen Delivery System Market Trends

The growing incidence of chronic diseases and expanding healthcare in Brazil are increasing the demand for effective treatment options, which is driving the development of the next-gen delivery systems. The companies are developing various injectables, implants, pumps, etc, which are being supported by investment from various sources, driving their acceptance rates.

Growing Disease Burden Propels MEA

MEA held 5% of the market share in 2025 and is expected to grow significantly in the next-gen delivery system market during the forecast period, due to growth in chronic diseases, which is increasing the demand for advanced delivery systems for target-specific actions. The growing healthcare infrastructure, investments, innovation, and government initiatives are also promoting their advancement, contributing to the market growth.

Saudi Arabia Next-Gen Delivery System Market Trends

The expanding healthcare infrastructure in Saudi Arabia is driving the development of various next-gen delivery systems. The growing chronic disease and government support are encouraging their development. Additionally, the increasing digitalization is also accelerating their innovations along with the development of new drug delivery devices.

Next-Gen Delivery System Market Value Chain Analysis

R&D

• The R&D of the next-gen delivery system focuses on the development of ligand conjugation platforms and precision-targeted nanocarriers to enhance the therapeutic efficacy.
• Key players: AstraZeneca, Ionis Pharmaceuticals, Novartis.

Clinical Trials and Regulatory Approvals

• The nanotoxicity, pharmacokinetic/pharmacodynamic profiles, and targeted accumulation are evaluated in the clinical trials and regulatory approvals of the next-gen delivery systems.
• Key players: AstraZeneca, Ionis Pharmaceuticals, Alnylam Pharmaceuticals.

Formulation and Final Dosage Preparation

• The formulation and final dosage preparation of the next-gen delivery system involves the encapsulation of therapeutics into lipid nanoparticles or ligand-anchored conjugates.
• Key players: Alnylam Pharmaceuticals, Evonik Industries, Moderna.

Packaging and Serialization

• Tamper-evident smart containers and block-enabled GS1 tracking to ensure traceability and cold chain integrity are used in the packaging and serialization of next gen delivery system.
• Key players: Antrares Vision Group, Stevanato Group, Adents.

Patient Support and Services

• At-home administration training and integration of digital health platforms are provided in the patient support and services of the next-gen delivery systems.
• Key players: Amgen, Novartis, AbbVie.

SWOT Analysis

Strengths

• The next-gen delivery systems offer improved drug efficacy by providing target-specific action and controlled release, which is increasing their adoption rates.
• Their reduced side effects and flexible dosing options are also increasing their use.
• Moreover, their ability to deliver complex drug formulations such as biologics and large molecules is also increasing their adoption rates.
• The presence of a wide range of delivery systems with easy administration methods are also increasing their acceptance rates.

Weaknesses

• Chances of device failures act as the major weakness in the next-gen delivery system market, limiting their use.
• The storage and stability issues of these systems also reduce their acceptance rates.

Opportunities

• The growing incidence of chronic diseases is increasing the adoption of the next-gen delivery systems.
• The growing advancements in the development of advanced therapies and personalized medicines are also increasing their use.
• Increasing demand for at-home devices is also increasing their adoption rates.
• Additionally, escalating technological innovations are also driving their advancements.

Threats

• The requirement for advanced technologies, raw materials, and specialized production facilities increases the development cost of the next-gen delivery systems, reducing their adoption rates.
• Stringent regulation and quality control also slow down their innovations.

Top Companies in the Next-Gen Delivery System Market

• F. Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• Becton, Dickinson and Company
• Genmab A/S
• Sanofi
• GlaxoSmithKline plc
• AbbVie Inc.
• Bayer AG
• AstraZeneca.
• Gilead Sciences, Inc.
• Amgen, Inc.
• Boehringer Ingelheim

Next-Gen Delivery System Market Top Vendors and Their Offerings

Latest Announcements by Industry Leaders

• In June 2025, CEO and co-founder at Bexorg, MD, PhD, Zvonimir Vrselja, stated that, with the help of their technology, which offers preclinical testing of any therapeutic in metabolically active whole human brain, be it diseased or non-diseased, can be achieved. Furthermore, the data collected through these platforms allows them to validate new biomarkers or targets for understanding pharmacokinetic and pharmacodynamic profiles, as well as the safety and effectiveness of drugs. He further stated that they are pleased to form the collaboration with Biohaven, which will help them to accelerate their two preclinical programmes and discover new CNS therapies in a precise and faster manner.
• In March 2025, the president and representative director of Taiho Pharmaceutical, Masayuki Kobayashi, stated that they are delighted to form a collaboration with Araris. Furthermore, the collaboration also allows the use of AraLinQ, which is an innovative technology used for next-generation ADC drug discovery. He further stated that this collaboration and technological platform, along with the experience and knowledge of Araris, will help them in ADC drug discovery, enhance their development pipeline, as well as will help in expanding and solidifying the drug discovery capabilities and portfolio of Taiho. Furthermore, they are looking forward to developing innovative drugs for patients worldwide with this partnership.

What are the Recent Developments in the Next-Gen Delivery System Market?

• In June 2025, a milestone was achieved by the Galway-headquartered Neurent Medical, which is a leader in pioneering non-surgical solutions for chronic sinonasal inflammatory diseases, for its next generation Neuromark system, used for the treatment of patients suffering from chronic rhinitis, as it was announced to have been granted 510(k) clearance by the US Food and Drug Administration (FDA).
• In May 2025, a novel drug delivery system for colon cancer was developed with the use of cross-linked nanoparticles derived from a natural resin, that is mastic gum (MG), by a collaboration between researchers from Andhra Pradesh and scientists from Saudi Arabia and the UAE.

Segments Covered in the Report

By Product Type

• Oral Drug Delivery Systems
  
  • Tablets
  • Capsules
  • Controlled Release Formulations
• Injectable Drug Delivery Systems
  
  • Prefilled Syringes
  • Auto-injectors
  • Pen Injectors
  • Wearable Injectors
• Pulmonary Drug Delivery Systems
  
  • Dry Powder Inhalers (DPI)
  • Metered Dose Inhalers (MDI)
  • Nebulizers
• Transdermal Drug Delivery Systems
  
  • Patches
  • Gels
  • Microneedle Systems
• Implantable Drug Delivery Systems
  
  • Drug-Eluting Stents
  • Biodegradable Implants
• Ocular Drug Delivery Systems
  
  • Eye Drops
  • Ocular Inserts

By Technology

• Nanotechnology-Based Delivery
  
  • Liposomes
  • Polymeric Nanoparticles
  • Solid Lipid Nanoparticles
• Targeted Drug Delivery
  
  • Ligand-Based Targeting
  • Antibody-Drug Conjugates
• Controlled & Sustained Release
  
  • Osmotic Systems
  • Matrix Systems
• Smart Drug Delivery Systems
  
  • Stimuli-Responsive Systems
  • Digital/Connected Devices

By Route of Administration

• Oral
• Parenteral
• Inhalation
• Transdermal
• Ocular

By Application

• Oncology
• Cardiovascular Diseases
• Diabetes
• Infectious Diseases
• Neurological Disorders
• Respiratory Diseases

By End User

• Hospitals
• Home Care Settings
• Specialty Clinics
• Ambulatory Surgical Centers

By Region

• North America
  
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• Latin America
  
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe
  
  • Western Europe
    
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe
    
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific
  
  • China
  • Taiwan
  • India
  • Japan
  • Australia
  • New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  
  • GCC Countries
    
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA